CClinicalTrials.gg
Active, not recruitingNCT07739953Updated Jul 31, 2026

Development and Clinical Application of ApoC3 Protein as a Predictive Biomarker for Insulin Resistance in Polycystic Ovary Syndrome

An observational study in PCOS (Polycystic Ovary Syndrome), sponsored by Guangdong Women and Children Hospital. Active, not recruiting at 1 site in China. Open to female participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Guangdong Women and Children Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
16 Years to 45 Years
Sex
Female
01

Study summary

Polycystic Ovary Syndrome (PCOS) is the most common reproductive endocrine disorder causing infertility and miscarriage in women. The insulin resistance state in PCOS patients (PCOS with insulin resistance, PCOS-IR) not only affects their fertility but is also associated with a range of health issues, including type 2 diabetes mellitus, endometrial cancer, and spontaneous abortion during pregnancy. There is an urgent clinical need to explore sensitive serum biomarkers for the diagnosis of insulin resistance in PCOS. Our preliminary studies have demonstrated that apolipoprotein C-III (ApoC3) exhibits diagnostic efficacy for PCOS-IR and is positively correlated with HOMA-IR, for which we were granted a national invention patent in China in 2016. Building on our research foundation in PCOS insulin resistance, we have developed a rapid detection kit for the ApoC3 protein, enabling early screening of insulin resistance in PCOS. Furthermore, point-of-care testing (POCT) products can achieve rapid quantitative detection of biomarkers. This project has recently been funded by the Guangdong Provincial Department of Science and Technology under the 2024 Guangdong-Hong Kong-Macao Greater Bay Area International Innovation Center Construction Initiative (Guangdong-Hong Kong-Macao Joint Innovation Field).

02

Conditions studied

  • PCOS (Polycystic Ovary Syndrome)
03

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study included PCOS patients diagnosed according to the 2003 Rotterdam criteria (at least 2 of: oligo/anovulation, clinical/biochemical hyperandrogenism, or polycystic ovaries on ultrasound). Patients were divided into two groups:

PCOS-IR group: met PCOS criteria plus at least one of: HOMA-IR ≥ 2.5, fasting insulin ≥ 15 μIU/mL, or diagnosed IGT/T2DM.

PCOS-non-IR group: met PCOS criteria with HOMA-IR \< 2.5 and no glucose metabolism abnormalities.

Exclusion criteria: other endocrine disorders, medication use, severe systemic diseases, pregnancy/lactation, or poor sample quality.

Eligibility criteria

I. Diagnostic Criteria

The 2003 Rotterdam diagnostic criteria for PCOS jointly established by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM):

Clinical and/or biochemical signs of hyperandrogenism; Oligo-ovulation or anovulation; Ultrasound findings: ovarian volume ≥ 10 mL, and/or > 12 follicles with a diameter of 2-9 mm in a single section.

A diagnosis of PCOS can be established when at least two of the following three criteria are met: ovarian dysfunction, hyperandrogenism, and polycystic ovarian morphology on ultrasound.

II. Inclusion and Exclusion Criteria

  1. PCOS with Insulin Resistance (PCOS-IR)

    Inclusion Criteria:

    Meets the 2003 Rotterdam diagnostic criteria for PCOS (at least 2 of the following 3 items):

    ① Oligo-ovulation or anovulation;

    ② Clinical or biochemical signs of hyperandrogenism;

    ③ Polycystic ovaries on ultrasound (unilateral or ovarian volume ≥ 10 mL).

    Insulin resistance (IR), meeting at least 1 of the following 3 criteria:

    ① HOMA-IR ≥ 2.5;

    ② Fasting insulin ≥ 15 μIU/mL;

    ③ Diagnosed impaired glucose tolerance (IGT) or type 2 diabetes mellitus (T2DM).

    Exclusion Criteria:

    Other endocrine disorders; Medication effects; Severe systemic diseases; Special physiological conditions (e.g., pregnancy, lactation); Poor sample quality.

  2. PCOS without Insulin Resistance (PCOS-non-IR)

Inclusion Criteria:

Meets the PCOS diagnostic criteria (as above), with HOMA-IR \< 2.5 and no glucose metabolism abnormalities.

Exclusion Criteria: Same as above.

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • Otherobservational study

    Observational Study

05

What researchers measure

Primary outcomes

  1. adverse pregnancy outcomes and long-term complications such as type 2 diabetes mellitus

    Time frame: 1year

06

Study locations

1 site
  • Guangdong Women and Children Hospital
    Guangzhou, China
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07739953
Lead sponsor
Guangdong Women and Children Hospital
Responsible party
Li Li (Chief Physician, Guangdong Women and Children Hospital) — Principal investigator
First posted
Jul 31, 2026
Start date
Jun 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 31, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion